<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>Annals of Internal Medicine: Diarrhea Topic Collection</title>
    <link>http://annals.org/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Tue, 18 Dec 2012 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 09 Apr 2013 13:46:52 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@annals.org</managingEditor>
    <webMaster>webmaster@annals.org</webMaster>
    <item>
      <title>Probiotics for the Prevention of  Clostridium difficile –Associated Diarrhea A Systematic Review and Meta-analysis </title>
      <link>http://annals.org/article.aspx?articleID=1390418</link>
      <pubDate>Tue, 18 Dec 2012 00:00:00 GMT</pubDate>
      <author>Johnston BC, Ma SY, Goldenberg JZ, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Background:&lt;/div&gt;Antibiotic treatment may disturb the resistance of gastrointestinal flora to colonization. This may result in complications, the most serious of which is &lt;span style="font-style:italic;"&gt;Clostridium difficile&lt;/span&gt;–associated diarrhea (CDAD).&lt;div class="boxTitle"&gt;Purpose:&lt;/div&gt;To assess the efficacy and safety of probiotics for the prevention of CDAD in adults and children receiving antibiotics.&lt;div class="boxTitle"&gt;Data Sources:&lt;/div&gt;Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL, Allied and Complementary Medicine Database, Web of Science, and 12 gray-literature sources.&lt;div class="boxTitle"&gt;Study Selection:&lt;/div&gt;Randomized, controlled trials including adult or pediatric patients receiving antibiotics that compared any strain or dose of a specified probiotic with placebo or with no treatment control and reported the incidence of CDAD.&lt;div class="boxTitle"&gt;Data Extraction:&lt;/div&gt;Two reviewers independently screened potentially eligible articles; extracted data on populations, interventions, and outcomes; and assessed risk of bias. The Grading of Recommendations Assessment, Development and Evaluation guidelines were used to independently rate overall confidence in effect estimates for each outcome.&lt;div class="boxTitle"&gt;Data Synthesis:&lt;/div&gt;Twenty trials including 3818 participants met the eligibility criteria. Probiotics reduced the incidence of CDAD by 66% (pooled relative risk, 0.34 [95% CI, 0.24 to 0.49]; &lt;span style="font-style:italic;"&gt;I&lt;/span&gt;&lt;sup&gt;2&lt;/sup&gt; = 0%). In a population with a 5% incidence of antibiotic-associated CDAD (median control group risk), probiotic prophylaxis would prevent 33 episodes (CI, 25 to 38 episodes) per 1000 persons. Of probiotic-treated patients, 9.3% experienced adverse events, compared with 12.6% of control patients (relative risk, 0.82 [CI, 0.65 to 1.05]; &lt;span style="font-style:italic;"&gt;I&lt;/span&gt;&lt;sup&gt;2&lt;/sup&gt; = 17%).&lt;div class="boxTitle"&gt;Limitations:&lt;/div&gt;In 13 trials, data on CDAD were missing for 5% to 45% of patients. The results were robust to worst-plausible assumptions regarding event rates in studies with missing outcome data.&lt;div class="boxTitle"&gt;Conclusion:&lt;/div&gt;Moderate-quality evidence suggests that probiotic prophylaxis results in a large reduction in CDAD without an increase in clinically important adverse events.&lt;div class="boxTitle"&gt;Primary Funding Source:&lt;/div&gt;None.&lt;/span&gt;</description>
      <guid>http://annals.org/article.aspx?articleID=1390418</guid>
    </item>
  </channel>
</rss>